During its recent board meeting in Addis Ababa, Ethiopia, the Global Fund to Fight AIDS, Tuberculosis and Malaria approved $2.4 billion for the three diseases, PlusNews reports. The money is for the fund’s “ninth round of grants, bringing the total amount of approved funding since its inception in 2001 to $18.4 billion,” according to the publication.
GlobalPost Examines Investment In Community Care Workers In South Africa As PEPFAR Moves Toward Local Implementation Of Programming
“Nearly a decade after it came into being, the President’s Emergency Plan for AIDS Relief (PEPFAR) … is moving increasingly to support local leadership and implementation capacity” in South Africa, GlobalPost’s “Global Pulse” blog reports. “And given the South African health system’s weaknesses in the face of the magnitude of AIDS and TB, that means an investment in … lay listeners with just a few weeks of training,” who can discuss treatment and other issues with patients, the blog writes. The blog profiles Goodness Henama, “one of 22 community care workers in Wallacedene township, in the Cape Town suburb of Kraainfontein.”
In this post in Huffington Post’s “Impact” blog, Deborah Derrick, president of Friends of the Global Fight Against AIDS, Tuberculosis and Malaria, examines “the success of U.S. efforts to promote better global health through support for [PEPFAR] and the Global Fund to Fight AIDS, Tuberculosis and Malaria.” She highlights U.S. Secretary of State Hillary Clinton’s recent trip to Africa, writing that Clinton’s “encouraging words” at the Reach Out Mbuya health center in Uganda reinforced U.S. commitment to an AIDS-free generation. She notes both PEPFAR and the Global Fund have supported the center and adds that “through hundreds of similar local programs all over the world, the Global Fund provides treatment to 3.6 million people who are HIV-positive.”
Health workers with Medical Teams International, a medical non-governmental organization, “say they are overwhelmed” by high demand at five health clinics in two southwestern Ugandan refugee centers, PlusNews reports. The refugees, “many of whom came from conflict-prone areas of the Democratic Republic of Congo (DRC),” and local residents are in need of HIV and tuberculosis (TB) prevention information, and care and treatment services, according to the news service. “Uganda suffers from a chronic shortage of health workers — less than half of the vacant health positions are filled — but the recent influx of refugees fleeing violence in neighboring DRC has put even more pressure on [the region's] health services,” PlusNews writes. Physicians, who see 30 to 50 patients daily and often work double shifts, say gaps in the supplies of antiretroviral (ARV) and TB drugs poses concern, as does trying to follow-up with patients who may not return for visits, the news service notes (3/29).
“South Africa wants to test hundreds of thousands of miners for tuberculosis [TB] and ensure sufferers get treatment over the next year,” David Mametja, head of South African National Department of Health’s TB program, said Tuesday at a workshop organized by the Stop TB Partnership, the Associated Press/Washington Post reports. Mametja “said the government is concerned the high prevalence of the disease among miners is holding an entire region back in the fight against TB,” and that while “it may be impossible to reach the nearly 600,000 miners in South Africa in one year, even those at highest risk in the gold industry, … setting an ambitious target is a way to show ‘it’s not business as usual,’” the AP writes.
“One in 10 cases of tuberculosis in China cannot be treated by the most commonly-used drugs, driven by a lack of testing and misuse of medicine, according to a national survey that showed for the first time the size of the drug-resistant epidemic,” the Associated Press reports (Wong, 6/7). “‘In 2007, one third of the patients with new cases of tuberculosis and one half of the patients with previously treated tuberculosis had drug-resistant disease,’ said the study in the New England Journal of Medicine,” Agence France-Presse reports, adding, “Even more, the prevalence of multi-drug resistant [tuberculosis (MDR-TB)] in new cases (5.7 percent) was nearly twice the global average, said the study” (6/6).
“The potential for antiretroviral medicine to reduce transmission of HIV and tuberculosis has been demonstrated, but the challenges of using treatment to prevent infection will need to be tackled country by country, and with focus on people for whom it will have the biggest impact, the latest bulletin on HIV treatment from the World Health Organization says,” the Center for Global Health Policy’s “Science Speaks” blog reports. “WHO’s June 2012 Antiretroviral Treatment as Prevention (TasP) of HIV and TB Programmatic Update is the latest of a series of documents the organization says will lead to a completed set of guidelines on treatment and prevention in July 2013,” the blog reports, noting, “The organization also plans to release new recommendations in time for the July International AIDS Conference, addressing the preventative use of antiretroviral medicine by people who are uninfected but potentially exposed to HIV, including those involved in commercial sex work, in ongoing relationships with infected partners, and men who have sex with men” (6/18).
South African TB Conference Hears Demands From Advocacy Organizations To Improve, Decentralize Treatment
The 2012 South African TB Conference opened Tuesday night in Durban, with the Treatment Action Campaign, Section27, and Oxfam delivering “a memorandum containing five demands to conference organizers shortly before the opening,” health-e News Service reports. The organizations “called for patients with drug-resistant TB who were failing to respond to treatment to be given ‘access to the best available medicines,’” even if they are not yet approved by the Medicines Control Council; “the diagnosis of all people living with TB”; and “the decentralization of care for people with drug-resistant TB, enabling them to be treated at home instead of hospitalized for long periods,” the news service writes (Cullinan, 6/13).
After testing about 5,600 existing medications for their effectiveness against drug-resistant strains of tuberculosis (TB), researchers from Weill Cornell Medical College reported this week in the Proceedings of the National Academy of Sciences that oxyphenbutazone, “an anti-inflammatory medication marketed in the 1950s as Tandearil and still used in veterinary medicine,” killed both latent and active TB bacteria in test-tube experiments, the Los Angeles Times’ “Booster Shots” blog reports. The medication is inexpensive, estimated to cost two cents per day in developing countries, according to the researchers, but it needs to go through “a series of clinical trials in which researchers would flesh out, in a human population, the medication’s safety and effectiveness record at various doses, in different patient populations and at different stages of the disease,” the blog writes.
In a 200th anniversary article for the New England Journal of Medicine, Salmaan Keshavjee of the Department of Global Health and Social Medicine at Harvard Medical School and Paul Farmer of Partners in Health “seek to elucidate the reasons for the anemic response to drug-resistant tuberculosis [TB] by examining the recent history of tuberculosis policy,” they write. The authors outline the history of TB drug development and how the disease became resistant to myriad drugs, and write that by the 1970s, “[t]uberculosis, whether caused by drug-susceptible or drug-resistant strains, rarely made even medical headlines, in part because its importance as a cause of death continued to decline in areas in which headlines are written. They continue, “In the United States, federal funding for tuberculosis research was cut; consequently, drug discovery, development of diagnostics, and vaccine research ground almost to a halt.”